Glycodendrimers as new tools in the search for effective anti-HIV DC-based immunotherapies

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 972-984

  Córdoba, E Vacas ^a,b   Pion, M ^a,b   Rasines, B ^c   Filippini, D ^c   Komber, H ^c   Ionov, M ^d   Bryszewska, M ^d   Appelhans, D ^c   Munoz Fernandez M A ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

^d UNIVERSITY OF LODZ   (Poland)

Author keywords

Dendrimer; Dendritic cells; HIV; Maltose; Vaccine

Indexed keywords

ANTIGENS; CELLS; CYTOLOGY; DENDRIMERS; IMMUNE SYSTEM; MALTOSE; PEPTIDES; VACCINES;

CYTOKINES; DENDRITIC CELLS; FUNCTIONALIZED DENDRIMERS; GLYCODENDRIMERS; HIV INFECTION; MIGRATION ABILITY; PEPTIDE COMPLEX; POSITIVELY CHARGED;

DISEASES;

B7 ANTIGEN; CD4 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; DENDRIMER; DENDRITIC CELL VACCINE; GLYCODENDRIMER; HIV DERIVED PEPTIDE; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; MALTOSE; PEPTIDE; POLYPROPYLENEIMINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL VIABILITY; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMATURE DENDRITIC CELL; IMMUNOSTIMULATION; IMMUNOTHERAPY; MATURE DENDRITIC CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INTERACTION; STATIC ELECTRICITY; T LYMPHOCYTE;

DENDRIMER; DENDRITIC CELLS; HIV; MALTOSE; VACCINE;

BIOLOGICAL MARKERS; CELL DEATH; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOKINES; DENDRIMERS; DENDRITIC CELLS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; MALTOSE; PEPTIDES; PHENOTYPE; T-LYMPHOCYTES;

EID: 85047686888     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.03.004     Document Type: Article

References (40)

1. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 2008, 205:7-12.
2. Scherer E., Douek D., McMichael A. 25years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines. Clin Exp Immunol 2008, 154:6-14.
3. Gamble L.J., Matthews Q.L. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther 2010, 5:9-26.
4. Munier C.M., Andersen C.R., Kelleher A.D. HIV vaccines: progress to date. Drugs 2011, 71:387-414.
5. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15:284-292.
6. Garcia F., Routy J.P. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011, 29:6454-6463.
7. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
8. Jefford M., Maraskovsky E., Cebon J., Davis I.D. The use of dendritic cells in cancer therapy. Lancet Oncol 2001, 2:343-353.
9. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
10. Thara E., Dorff T.B., Pinski J.K., Quinn D.I. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas 2011, 69:296-303.
11. Trepiakas R., Berntsen A., Hadrup S.R., Bjorn J., Geertsen P.F., Straten P.T., et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 2010, 12:721-734.
12. Steinman R.M., Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002, 99:351-358.
13. Aline F., Brand D., Pierre J., Roingeard P., Severine M., Verrier B., et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009, 27:5284-5291.
14. Weber C., Drogoz A., David L., Domard A., Charles M.H., Verrier B., et al. Polysaccharide-based vaccine delivery systems: Macromolecular assembly, interactions with antigen presenting cells, and in vivo immunomonitoring. J Biomed Mater Res A 2010, 93:1322-1334.
15. Cruz L.J., Rueda F., Cordobilla B., Simon L., Hosta L., Albericio F., et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm 2011, 8:104-116.
16. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., et al. Targeted delivery of Toll-like receptor ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011.
17. Vu-Quang H., Yoo M.K., Jeong H.J., Lee H.J., Muthiah M., Rhee J.H., et al. Targeted delivery of mannan-coated superparamagnetic iron oxide nanoparticles to antigen-presenting cells for magnetic resonance-based diagnosis of metastatic lymph nodes in vivo. Acta Biomater 2011, 7:3935-3945.
18. Li H., Li Y., Jiao J., Hu H.M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 2011, 6:645-650.
19. Cho N.H., Cheong T.C., Min J.H., Wu J.H., Lee S.J., Kim D., et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol 2011, 6:675-682.
20. Sokolova V., Knuschke T., Buer J., Westendorf A.M., Epple M. Quantitative determination of the composition of multi-shell calcium phosphate-oligonucleotide nanoparticles and their application for the activation of dendritic cells. Acta Biomater 2011, 7:4029-4036.
21. Pion M., Serramia M.J., Diaz L., Bryszewska M., Gallart T., Garcia F., et al. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials 2010, 31:8749-8758.
22. Zhu A., Romero R., Huang J.B., Clark A., Petty H.R. Maltooligosaccharides from JEG-3 trophoblast-like cells exhibit immunoregulatory properties. Am J Reprod Immunol 2011, 65:54-64.
23. Cho H.J., Han S.E., Im S., Lee Y., Kim Y.B., Chun T., et al. Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16L1 protein and DNA as a vaccine co-delivery system. Biomaterials 2011, 32:4621-4629.
24. Song C.K., Jung S.H., Kim D.D., Jeong K.S., Shin B.C., Seong H. Disaccharide-modified liposomes and their in vitro intracellular uptake. Int J Pharm 2009, 380:161-169.
25. Chatwell L., Holla A., Kaufer B.B., Skerra A. The carbohydrate recognition domain of Langerin reveals high structural similarity with the one of DC-SIGN but an additional, calcium-independent sugar-binding site. Mol Immunol 2008, 45:1981-1994.
26. Ziemba B., Janaszewska A., Ciepluch K., Krotewicz M., Fogel W.A., Appelhans D., et al. In vivo toxicity of poly(propyleneimine) dendrimers. J Biomed Mater Res A 2011, 99:261-268.
27. Hobel S., Loos A., Appelhans D., Schwarz S., Seidel J., Voit B., et al. Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. J Control Release 2011, 149:146-158.
28. Fischer W., Claderon M., Ofek P., Satchi-Fainaro R., Haag R. siRNA transfection by dendritic core-shell nanocarriers. J Control Release 2010, 148:e89.
29. Klajnert B., Appelhans D., Komber H., Morgner N., Schwarz S., Richter S., et al. The influence of densely organized maltose shells on the biological properties of poly(propylene imine) dendrimers: new effects dependent on hydrogen bonding. Chem Eur J 2008, 14:7030-7041.
30. Mkandawire M., Pohl A., Gubarevich T., Lapina V., Appelhans D., Rodel G., et al. Selective targeting of green fluorescent nanodiamond conjugates to mitochondria in HeLa cells. J Biophotonics 2009, 2:596-606.
31. Appelhans D., Komber H., Quadir M.A., Richter S., Schwarz S., van der Vlist J., et al. Hyperbranched PEI with various oligosaccharide architectures: synthesis, characterization, ATP complexation, and cellular uptake properties. Biomacromolecules 2009, 10:1114-1124.
32. Garcia-Merino I., de Las Cuevas N., Jimenez J.L., Gallego J., Gomez C., Prieto C., et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009, 6:27.
33. Akagawa K.S., Takasuka N., Nozaki Y., Komuro I., Azuma M., Ueda M., et al. Generation of CD1+RelB+dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Blood 1996, 88:4029-4039.
34. Ciolkowski M., Palecz B., Appelhans D., Voit B., Klajnert B., Bryszewska M. The influence of maltose modified poly(propylene imine) dendrimers on hen egg white lysozyme structure and thermal stability. Colloids Surf B Biointerfaces 2012, 95:103-108.
35. Kameyama S., Horie M., Kikuchi T., Omura T., Tadokoro A., Takeuchi T., et al. Acid wash in determining cellular uptake of Fab/cell-permeating peptide conjugates. Biopolymers 2007, 88:98-107.
36. Klementieva O., Benseny-Cases N., Gella A., Appelhans D., Voit B., Cladera J. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity. Biomacromolecules 2011, 12:3903-3909.
37. Park I.Y., Kim I.Y., Yoo M.K., Choi Y.J., Cho M.H., Cho C.S. Mannosylated polyethylenimine coupled mesoporous silica nanoparticles for receptor-mediated gene delivery. Int J Pharm 2008, 359:280-287.
38. Carrillo-Conde B., Song E.H., Chavez-Santoscoy A., Phanse Y., Ramer-Tait A.E., Pohl N.L., et al. Mannose-functionalized "pathogen-like" polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol Pharm 2011, 8:1877-1886.
39. Irache J.M., Salman H.H., Gamazo C., Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 2008, 5:703-724.
40. Torres M.P., Wilson-Welder J.H., Lopac S.K., Phanse Y., Carrillo-Conde B., Ramer-Tait A.E., et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater 2011, 7:2857-2864.